Latest Diagnostics News

ResMed Inc. posted a 10% rise in fiscal 2026 revenue to $5.65 billion, bolstered by the acquisition of Noctrix Health and an agreement to sell its MatrixCare business. The company continues to invest in AI-powered digital health solutions amid ongoing patent litigation and a shifting regulatory landscape.

Archer Materials has pinpointed a capillary blood collection method that matches venous samples in haemolysis levels, advancing its potassium Biosensor development towards integrated clinical testing.

Proteomics International has achieved a key patent acceptance in Australia for its PromarkerEndo blood test, reinforcing its intellectual property portfolio and commercialisation strategy in a major healthcare market.

Integral Diagnostics (ASX: IDX) posted strong preliminary FY26 results with revenue nearing $790 million and operating EBITDA up 30%, while announcing Jenny Martin as incoming CFO amid leadership transitions.

Imricor Medical Systems has ignited its US commercial operations with rapid adoption by top pediatric hospitals, buoyed by FDA pediatric clearances and clinical trial progress.

Clarity Pharmaceuticals has presented compelling clinical evidence that its investigational 64Cu-SAR-bisPSMA diagnostic and 67Cu-SAR-bisPSMA therapeutic candidates outperform current standards in prostate cancer care, positioning the company for regulatory and commercial milestones.

Integral Diagnostics has installed Jason Martinez as its new CEO, marking a leadership change as the company prepares to present its FY26 results. Martinez brings over 20 years of diagnostic imaging experience and aims to drive growth and innovation following the retirement of long-serving CEO Ian Kadish.

Lumos Diagnostics has landed a US$767,800 purchase order for its FebriDx rapid test from PHASE Scientific, marking a key step in commercialising its FDA-approved product ahead of the US flu season.

Clarity Pharmaceuticals bolsters its commercial readiness with a $178.3 million cash reserve and a key US manufacturing agreement, while clinical trials for its prostate cancer imaging and therapeutic agents progress with promising data.

Singular Health deepens US healthcare foothold with ongoing Triple-S contract talks, PNS licence expansion, and Miami-Dade educational rollout, supported by a solid $10.1 million cash reserve.

IMEXHS Limited posted a 21% revenue increase in Q2 FY26, driven by a landmark public tender in Mexico deploying its AI-powered Aquila+ radiology platform. The company’s proprietary AI agents are now operational in live environments, supporting its strategy to own the full radiology workflow.

Far East Gold has boosted its stake in the Idenburg Gold Project to 51%, revealing a 44% increase in inferred gold resources to 780,000 ounces. The company’s Independent Board Committee advises shareholders to reject an unsolicited takeover bid from Xingye Gold, which an expert deems undervalues the company.